Literature DB >> 27297116

Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.

Lotan Levin1, Shani Srour1, Jared Gartner2, Oxana Kapitansky1, Nouar Qutob3, Shani Dror1, Tamar Golan1, Roy Dayan1, Ronen Brener4, Tamar Ziv5, Mehdi Khaled6, Ora Schueler-Furman7, Yardena Samuels3, Carmit Levy8.   

Abstract

Epidemiological studies suggest a direct link between melanoma and Parkinson's disease (PD); however, the underlying molecular basis is unknown. Since mutations in Parkin are the major driver of early-onset PD and Parkin was recently reported to play a role in cancer development, we hypothesized that Parkin links melanoma and PD. By analyzing whole exome/genome sequencing of Parkin from 246 melanoma patients, we identified five non-synonymous mutations, three synonymous mutations, and one splice region variant in Parkin in 3.6% of the samples. In vitro analysis showed that wild-type Parkin plays a tumor suppressive role in melanoma development resulting in cell-cycle arrest, reduction of metabolic activity, and apoptosis. Using a mass spectrometry-based analysis, we identified potential Parkin substrates in melanoma and generated a functional protein association network. The activity of mutated Parkin was assessed by protein structure modeling and examination of Parkin E3 ligase activity. The Parkin-E28K mutation impairs Parkin ubiquitination activity and abolishes its tumor suppressive effect. Taken together, our analysis of genomic sequence and in vitro data indicate that Parkin is a potential link between melanoma and Parkinson's disease. Our findings suggest new approaches for early diagnosis and treatment against both diseases.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Melanoma; Mutation; Parkin; Parkinson's disease

Mesh:

Substances:

Year:  2016        PMID: 27297116     DOI: 10.1016/j.jgg.2016.05.005

Source DB:  PubMed          Journal:  J Genet Genomics        ISSN: 1673-8527            Impact factor:   4.275


  6 in total

1.  E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.

Authors:  Valentina Montagnani; Luisa Maresca; Alessandro Apollo; Sara Pepe; Ryan M Carr; Martin E Fernandez-Zapico; Barbara Stecca
Journal:  J Biol Chem       Date:  2020-09-16       Impact factor: 5.157

2.  Overlapping genetic architecture between Parkinson disease and melanoma.

Authors:  Umber Dube; Laura Ibanez; John P Budde; Bruno A Benitez; Albert A Davis; Oscar Harari; Mark M Iles; Matthew H Law; Kevin M Brown; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2019-12-16       Impact factor: 17.088

Review 3.  Linking Parkinson's Disease and Melanoma: Interplay Between α-Synuclein and Pmel17 Amyloid Formation.

Authors:  Dexter N Dean; Jennifer C Lee
Journal:  Mov Disord       Date:  2021-05-22       Impact factor: 9.698

Review 4.  Ubiquitination in melanoma pathogenesis and treatment.

Authors:  Jinyuan Ma; Weinan Guo; Chunying Li
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

5.  Parkin regulates translesion DNA synthesis in response to UV radiation.

Authors:  Xuefei Zhu; Xiaolu Ma; Yingfeng Tu; Min Huang; Hongmei Liu; Fengli Wang; Juanjuan Gong; Jiuqiang Wang; Xiaoling Li; Qian Chen; Hongyan Shen; Shu Zhu; Yun Wang; Yang Liu; Caixia Guo; Tie-Shan Tang
Journal:  Oncotarget       Date:  2017-05-30

Review 6.  Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms.

Authors:  Anindita Bose; Gregory A Petsko; David Eliezer
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.